Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using [18]F-fluoromisonidazole PET/CT: a pilot study
| Autor: | Matthieu Hatt, Loïc Campion, Philippe Meingan, Stéphane Supiot, Christine Kandel-Aznar, Caroline Rousseau, Ludovic Ferrer, Stéphane Guerif, Dimitris Visvikis, M. Doré, François Paris, Catherine Cheze-Le-Rest, Gregory Delpon, Vincent Potiron |
|---|---|
| Přispěvatelé: | Endothelium Radiobiology and Targeting (CRCINA-ÉQUIPE 14), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre hospitalier universitaire de Nantes (CHU Nantes), Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Laboratoire de Traitement de l'Information Medicale (LaTIM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), This work was supported by the Institut National du Cancer (INCA PAIR-prostate 2010), the Association pour la Recherche sur le Cancer, the Ligue Nationale Contre le Cancer and the Région Bretagne and Pays de la Loire., Institut National de la Santé et de la Recherche Médicale (INSERM)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-IMT Atlantique (IMT Atlantique), Bernardo, Elizabeth |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Misonidazole medicine.medical_treatment [SDV.CAN]Life Sciences [q-bio]/Cancer 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine [SDV.CAN] Life Sciences [q-bio]/Cancer Prostate Radioresistance Medicine HIF FAZA PET-CT Tumor hypoxia business.industry hypoxia medicine.disease prostate cancer 3. Good health Radiation therapy 030104 developmental biology medicine.anatomical_structure Oncology chemistry 030220 oncology & carcinogenesis misonidazole business Nuclear medicine FMISO Research Paper |
| Zdroj: | Oncotarget Oncotarget, Impact journals, 2018, 9 (11), pp.10005-10015. ⟨10.18632/oncotarget.24234⟩ Oncotarget, 2018, 9 (11), pp.10005-10015. ⟨10.18632/oncotarget.24234⟩ |
| ISSN: | 1949-2553 |
| Popis: | International audience; Purpose: Hypoxia is a major factor in prostate cancer aggressiveness and radioresistance. Predicting which patients might be bad candidates for radiotherapy may help better personalize treatment decisions in intermediate-risk prostate cancer patients. We assessed spatial distribution of [18]F-Misonidazole (FMISO) PET/CT uptake in the prostate prior to radiotherapy treatment.Materials and Methods: Intermediate-risk prostate cancer patients about to receive high-dose (>74 Gy) radiotherapy to the prostate without hormonal treatment were prospectively recruited between 9/2012 and 10/2014. Prior to radiotherapy, all patients underwent a FMISO PET/CT as well as a MRI and [18]F-choline-PET. [18]F-choline and FMISO-positive volumes were semi-automatically determined using the fuzzy locally adaptive Bayesian (FLAB) method. In FMISO-positive patients, a dynamic analysis of early tumor uptake was performed. Group differences were assessed using the Wilcoxon signed rank test. Parameters were correlated using Spearman rank correlation.Results: Of 27 patients (median age 76) recruited to the study, 7 and 9 patients were considered positive at 2.5h and 3.5h FMISO PET/CT respectively. Median SUV[max] and SUV[max] tumor to muscle (T/M) ratio were respectively 3.4 and 3.6 at 2.5h, and 3.2 and 4.4 at 3.5h. The median FMISO-positive volume was 1.1 ml.Conclusions: This is the first study regarding hypoxia imaging using FMISO in prostate cancer showing that a small FMISO-positive volume was detected in one third of intermediate-risk prostate cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|